Clinical Trial Results:
An Uncontrolled, Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Maintenance of Effect of BIIB074 (Vixotrigine) in Subjects With Neuropathic Pain From Lumbosacral Radiculopathy
Summary
|
|
EudraCT number |
2015-004796-68 |
Trial protocol |
LV GB SK AT ES CZ BG BE NL IT |
Global end of trial date |
07 Feb 2019
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
19 Feb 2020
|
First version publication date |
19 Feb 2020
|
Other versions |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
1014802-204
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
NCT02957617 | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
Biogen
|
||
Sponsor organisation address |
225 Binney Street, Cambridge, United States, 02142
|
||
Public contact |
Biogen Study Medical Director, Biogen, +1 866-633-4636, clinicaltrials@biogen.com
|
||
Scientific contact |
Biogen Study Medical Director, Biogen, +1 866-633-4636, clinicaltrials@biogen.com
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
07 Feb 2019
|
||
Is this the analysis of the primary completion data? |
No
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
07 Feb 2019
|
||
Was the trial ended prematurely? |
Yes
|
||
General information about the trial
|
|||
Main objective of the trial |
The primary objective of the study is to evaluate the long-term safety and tolerability of BIIB074 in subjects with neuropathic Pain From Lumbosacral Radiculopathy (PLSR). A secondary objective is to investigate the maintenance of effect during long-term treatment with BIIB074 in subjects with neuropathic PLSR. For all efficacy assessments, baseline will be prior to randomisation into Study 1014802-203. Another secondary objective is to evaluate the impact of treatment with BIIB074 on quality of life (QoL).
|
||
Protection of trial subjects |
Written informed consent was obtained from each subject or subject’s legally authorized representative (e.g., parent or legal guardian), as applicable, prior to evaluations performed for eligibility. Subjects or the subject’s legally authorized representative were given adequate time to review the information in the informed consent/assent and were allowed to ask, and have answered, questions concerning all portions of the conduct of the study.
|
||
Background therapy |
- | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
10 Feb 2017
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
Yes
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Bulgaria: 82
|
||
Country: Number of subjects enrolled |
Czech Republic: 63
|
||
Country: Number of subjects enrolled |
Serbia: 45
|
||
Country: Number of subjects enrolled |
Georgia: 29
|
||
Country: Number of subjects enrolled |
Slovakia: 29
|
||
Country: Number of subjects enrolled |
Spain: 15
|
||
Country: Number of subjects enrolled |
United Kingdom: 13
|
||
Country: Number of subjects enrolled |
Romania: 10
|
||
Country: Number of subjects enrolled |
Latvia: 7
|
||
Country: Number of subjects enrolled |
Belgium: 5
|
||
Country: Number of subjects enrolled |
France: 2
|
||
Country: Number of subjects enrolled |
Estonia: 1
|
||
Country: Number of subjects enrolled |
Italy: 1
|
||
Worldwide total number of subjects |
302
|
||
EEA total number of subjects |
228
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
256
|
||
From 65 to 84 years |
46
|
||
85 years and over |
0
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||
Recruitment
|
|||||||||||||||||||||||||||||||||||||||||||||||||||
Recruitment details |
Subjects were enrolled at 50 investigative sites in 13 countries in Eastern and Western Europe from 10 February 2017 to 07 February 2019. | ||||||||||||||||||||||||||||||||||||||||||||||||||
Pre-assignment
|
|||||||||||||||||||||||||||||||||||||||||||||||||||
Screening details |
Qualified subjects who participated in study 1014802-203 (203) were enrolled in this open-label extension study 1014802-204 (204). One subject who did not receive Study 203 randomised treatment was dosed in Study 204. | ||||||||||||||||||||||||||||||||||||||||||||||||||
Period 1
|
|||||||||||||||||||||||||||||||||||||||||||||||||||
Period 1 title |
Overall Study (overall period)
|
||||||||||||||||||||||||||||||||||||||||||||||||||
Is this the baseline period? |
Yes | ||||||||||||||||||||||||||||||||||||||||||||||||||
Allocation method |
Not applicable
|
||||||||||||||||||||||||||||||||||||||||||||||||||
Blinding used |
Not blinded | ||||||||||||||||||||||||||||||||||||||||||||||||||
Arms
|
|||||||||||||||||||||||||||||||||||||||||||||||||||
Are arms mutually exclusive |
Yes
|
||||||||||||||||||||||||||||||||||||||||||||||||||
Arm title
|
BIIB074 (203:Not Dosed Cohort) | ||||||||||||||||||||||||||||||||||||||||||||||||||
Arm description |
BIIB074 (vixotrigine) 350 mg orally twice daily (BID), which could be reduced to 200 mg based on tolerability for up to 12 months in Study 204. (Cohort includes subjects who were not dosed in Study 203.) | ||||||||||||||||||||||||||||||||||||||||||||||||||
Arm type |
Experimental | ||||||||||||||||||||||||||||||||||||||||||||||||||
Investigational medicinal product name |
BIIB074
|
||||||||||||||||||||||||||||||||||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||||||||||||||||||||||||||||||||||
Other name |
CNV1014802, GSK1014802, vixotrigine
|
||||||||||||||||||||||||||||||||||||||||||||||||||
Pharmaceutical forms |
Film-coated tablet
|
||||||||||||||||||||||||||||||||||||||||||||||||||
Routes of administration |
Oral use
|
||||||||||||||||||||||||||||||||||||||||||||||||||
Dosage and administration details |
BIIB074 tablets, orally, twice daily (BID) for up to 12 months.
|
||||||||||||||||||||||||||||||||||||||||||||||||||
Arm title
|
BIIB074 (203:Placebo Cohort) | ||||||||||||||||||||||||||||||||||||||||||||||||||
Arm description |
BIIB074 (vixotrigine) 350 mg orally BID, which could be reduced to 200 mg based on tolerability for up to 12 months in Study 204. (Cohort includes subjects who received Placebo for up to 12 weeks in Study 203.) | ||||||||||||||||||||||||||||||||||||||||||||||||||
Arm type |
Experimental | ||||||||||||||||||||||||||||||||||||||||||||||||||
Investigational medicinal product name |
BIIB074
|
||||||||||||||||||||||||||||||||||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||||||||||||||||||||||||||||||||||
Other name |
CNV1014802, GSK1014802, vixotrigine
|
||||||||||||||||||||||||||||||||||||||||||||||||||
Pharmaceutical forms |
Film-coated tablet
|
||||||||||||||||||||||||||||||||||||||||||||||||||
Routes of administration |
Oral use
|
||||||||||||||||||||||||||||||||||||||||||||||||||
Dosage and administration details |
BIIB074 tablets, orally, BID for up to 12 months.
|
||||||||||||||||||||||||||||||||||||||||||||||||||
Arm title
|
BIIB074 (203:BIIB074 200 mg Cohort) | ||||||||||||||||||||||||||||||||||||||||||||||||||
Arm description |
BIIB074 (vixotrigine) 350 mg orally BID, which could be reduced to 200 mg based on tolerability for up to 12 months in Study 204. (Cohort includes subjects who received BIIB074 200 mg for up to 12 weeks in Study 203.) | ||||||||||||||||||||||||||||||||||||||||||||||||||
Arm type |
Experimental | ||||||||||||||||||||||||||||||||||||||||||||||||||
Investigational medicinal product name |
BIIB074
|
||||||||||||||||||||||||||||||||||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||||||||||||||||||||||||||||||||||
Other name |
CNV1014802, GSK1014802, vixotrigine
|
||||||||||||||||||||||||||||||||||||||||||||||||||
Pharmaceutical forms |
Film-coated tablet
|
||||||||||||||||||||||||||||||||||||||||||||||||||
Routes of administration |
Oral use
|
||||||||||||||||||||||||||||||||||||||||||||||||||
Dosage and administration details |
BIIB074 tablets, orally ,BID for up to 12 months.
|
||||||||||||||||||||||||||||||||||||||||||||||||||
Arm title
|
BIIB074 (203:BIIB074 350 mg Cohort) | ||||||||||||||||||||||||||||||||||||||||||||||||||
Arm description |
BIIB074 (vixotrigine) 350 mg orally BID, which could be reduced to 200 mg based on tolerability for up to 12 months in Study 204. (Cohort includes subjects who received BIIB074 350 mg for up to 12 weeks in Study 203.) | ||||||||||||||||||||||||||||||||||||||||||||||||||
Arm type |
Experimental | ||||||||||||||||||||||||||||||||||||||||||||||||||
Investigational medicinal product name |
BIIB074
|
||||||||||||||||||||||||||||||||||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||||||||||||||||||||||||||||||||||
Other name |
CNV1014802, GSK1014802, vixotrigine
|
||||||||||||||||||||||||||||||||||||||||||||||||||
Pharmaceutical forms |
Film-coated tablet
|
||||||||||||||||||||||||||||||||||||||||||||||||||
Routes of administration |
Oral use
|
||||||||||||||||||||||||||||||||||||||||||||||||||
Dosage and administration details |
BIIB074 tablets, orally, BID for up to 12 months.
|
||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
BIIB074 (203:Not Dosed Cohort)
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
BIIB074 (vixotrigine) 350 mg orally twice daily (BID), which could be reduced to 200 mg based on tolerability for up to 12 months in Study 204. (Cohort includes subjects who were not dosed in Study 203.) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
BIIB074 (203:Placebo Cohort)
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
BIIB074 (vixotrigine) 350 mg orally BID, which could be reduced to 200 mg based on tolerability for up to 12 months in Study 204. (Cohort includes subjects who received Placebo for up to 12 weeks in Study 203.) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
BIIB074 (203:BIIB074 200 mg Cohort)
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
BIIB074 (vixotrigine) 350 mg orally BID, which could be reduced to 200 mg based on tolerability for up to 12 months in Study 204. (Cohort includes subjects who received BIIB074 200 mg for up to 12 weeks in Study 203.) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
BIIB074 (203:BIIB074 350 mg Cohort)
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
BIIB074 (vixotrigine) 350 mg orally BID, which could be reduced to 200 mg based on tolerability for up to 12 months in Study 204. (Cohort includes subjects who received BIIB074 350 mg for up to 12 weeks in Study 203.) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
BIIB074 (203:Not Dosed Cohort)
|
||
Reporting group description |
BIIB074 (vixotrigine) 350 mg orally twice daily (BID), which could be reduced to 200 mg based on tolerability for up to 12 months in Study 204. (Cohort includes subjects who were not dosed in Study 203.) | ||
Reporting group title |
BIIB074 (203:Placebo Cohort)
|
||
Reporting group description |
BIIB074 (vixotrigine) 350 mg orally BID, which could be reduced to 200 mg based on tolerability for up to 12 months in Study 204. (Cohort includes subjects who received Placebo for up to 12 weeks in Study 203.) | ||
Reporting group title |
BIIB074 (203:BIIB074 200 mg Cohort)
|
||
Reporting group description |
BIIB074 (vixotrigine) 350 mg orally BID, which could be reduced to 200 mg based on tolerability for up to 12 months in Study 204. (Cohort includes subjects who received BIIB074 200 mg for up to 12 weeks in Study 203.) | ||
Reporting group title |
BIIB074 (203:BIIB074 350 mg Cohort)
|
||
Reporting group description |
BIIB074 (vixotrigine) 350 mg orally BID, which could be reduced to 200 mg based on tolerability for up to 12 months in Study 204. (Cohort includes subjects who received BIIB074 350 mg for up to 12 weeks in Study 203.) |
|
|||||||||||||||||||||||||||||||
End point title |
Number of Subjects Experiencing Adverse Events (AEs) and Serious Adverse Events (SAEs) [1] | ||||||||||||||||||||||||||||||
End point description |
An AE is defined as any untoward medical occurrence in a clinical investigation subject administered a pharmaceutical product; it does not necessarily have to have a causal relationship with this treatment. An AE could therefore, be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product. A SAE is any untoward medical occurrence or effect that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability / incapacity, is a congenital anomaly / birth defect or is medically important due to other reasons than the above mentioned criteria. Safety Population included all subjects who received at least 1 dose of study treatment in this open-label extension study.
|
||||||||||||||||||||||||||||||
End point type |
Primary
|
||||||||||||||||||||||||||||||
End point timeframe |
Up to 398 Days in Study 204
|
||||||||||||||||||||||||||||||
Notes [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: Not all arms in the Baseline Period are applicable for this endpoint. |
|||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||
End point title |
Change from Baseline to Week 52 in the Weekly Average of the Daily Neuropathic Pain Score on the Pain Intensity Numerical Rating Scale (PI-NRS) [2] | ||||||||||||||||
End point description |
Subjects were asked every evening to rate their overall neuropathic pain in the worse affected leg (identified on Day 1 of Study 203) for the last 24-hour period. PI-NRS is an 11-point pain intensity numerical rating scale (PI-NRS), where 0=no pain and 10=pain as bad as you can imagine. A negative change from Baseline indicates improvement. The efficacy population included all subjects who received at least 1 dose of study treatment in this extension Study 204, and who were randomised and received at least 1 dose of study treatment in the double-blind period in Study 203. Number of subjects analysed is the number of subjects with evaluable data at the given timepoint.
|
||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
Baseline (1-week prior to randomisation in Study 203) to Week 52 in Study 204
|
||||||||||||||||
Notes [2] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: Not all arms in the Baseline Period are applicable for this endpoint. |
|||||||||||||||||
|
|||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||
End point title |
Number of Subjects with 50% Neuropathic Pain Reduction Response [3] | ||||||||||||||||
End point description |
Response is defined as a ≥50% reduction in the weekly average of the daily neuropathic pain score from Baseline to Week 52. The efficacy population included all subjects who received at least 1 dose of study treatment in this extension Study 204, and who were randomised and received at least 1 dose of study treatment in the double-blind period in Study 203. Number of subjects analysed is the number of subjects with evaluable data at the given timepoint.
|
||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
Baseline (1-week prior to randomisation in 203) to Week 52 in Study 204
|
||||||||||||||||
Notes [3] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: Not all arms in the Baseline Period are applicable for this endpoint. |
|||||||||||||||||
|
|||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||
End point title |
Number of Subjects with 30% Neuropathic Pain Reduction Response [4] | ||||||||||||||||
End point description |
Response is defined as a ≥30% reduction in the weekly average of the daily neuropathic pain score from Baseline to Week 52. The efficacy population included all subjects who received at least 1 dose of study treatment in this extension Study 204, and who were randomised and received at least 1 dose of study treatment in the double-blind period in Study 203. Number of subjects analysed is the number of subjects with evaluable data at the given timepoint.
|
||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
Baseline (1-week prior to randomisation in 203) to Week 52 in Study 204
|
||||||||||||||||
Notes [4] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: Not all arms in the Baseline Period are applicable for this endpoint. |
|||||||||||||||||
|
|||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||||
End point title |
Change from Baseline at Each Visit in the Weekly Average of the Daily Neuropathic Pain Score [5] | ||||||||||||||||||||||||||||||||||||
End point description |
Subjects were asked every evening to rate their overall neuropathic pain for the last 24-hour period using the 11-point PI-NRS, where 0=no pain and 10=pain as bad as you can imagine A negative change from Baseline indicates improvement. The efficacy population included all subjects who received at least 1 dose of study treatment in this extension Study 204, and who were randomised and received at least 1 dose of study treatment in the double-blind period in Study 203. Number of subjects analysed is the number of subjects with evaluable data at the given timepoint.
|
||||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||||||||||||||
End point timeframe |
Baseline (1-week period prior to randomisation in 203) through Weeks 2, 4, 13, 26, 39 of Study 204
|
||||||||||||||||||||||||||||||||||||
Notes [5] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: Not all arms in the Baseline Period are applicable for this endpoint. |
|||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||
End point title |
Change from Baseline to Week 52 in the Weekly Average of the Daily Pain Score for Low Back Pain [6] | ||||||||||||||||
End point description |
Subjects were asked every evening to rate their overall low back pain for the last 24-hour period using the 11-point PI-NRS, where 0=no pain and 10= pain as bad as you can imagine. A negative change from Baseline indicates improvement. The efficacy population included all subjects who received at least 1 dose of study treatment in this extension Study 204, and who were randomised and received at least 1 dose of study treatment in the double-blind period in Study 203. Number of subjects analysed is the number of subjects with evaluable data at the given timepoint.
|
||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
Baseline (1-week prior to randomisation in Study 203) to Week 52 of Study 204
|
||||||||||||||||
Notes [6] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: Not all arms in the Baseline Period are applicable for this endpoint. |
|||||||||||||||||
|
|||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||
End point title |
Number of Patient Global Impression of Change (PGIC) Responders [7] | ||||||||||||||||
End point description |
PGIC is a 7-point self-report scale depicting a subject's rating of overall improvement. Subjects rated their change as "very much improved," "much improved," "minimally improved," "no change," "minimally worse," "much worse," or "very much worse." A responder is defined as a subject with a response of “very much improved” or “much improved”. The efficacy population included all subjects who received at least 1 dose of study treatment in this extension Study 204, and who were randomised and received at least 1 dose of study treatment in the double-blind period in Study 203. Number of subjects analysed is the number of subjects with evaluable data at the given timepoint.
|
||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
Baseline (Day 1 of Study 203) to Week 52 of Study 204
|
||||||||||||||||
Notes [7] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: Not all arms in the Baseline Period are applicable for this endpoint. |
|||||||||||||||||
|
|||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||
End point title |
Change from Baseline to Week 52 on the Oswestry Disability Index (ODI) [8] | ||||||||||||||||
End point description |
The ODI is a 10-item questionnaire that evaluates how back (or leg) pain affects the ability to manage in everyday life: Pain intensity, Personal care, Lifting, Walking, Sitting, Standing, Sleeping, Sex life, Social life and Traveling. Each question is rated on a 6-point scale: 0(best) to 5(worst); with higher scores indicating higher level of pain for a total possible score of 0 to 50.
|
||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
Baseline to Week 52
|
||||||||||||||||
Notes [8] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: Not all arms in the Baseline Period are applicable for this endpoint. |
|||||||||||||||||
|
|||||||||||||||||
Notes [9] - Study was terminated; only Key Secondary endpoints were analysed. [10] - Study was terminated; only Key Secondary endpoints were analysed. [11] - Study was terminated; only Key Secondary endpoints were analysed. |
|||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||
End point title |
Change from Baseline to Week 52 in the Weekly Average of the Daily Sleep Score as Assessed by the Sleep Numerical Rating Scale (S-NRS) [12] | ||||||||||||||||
End point description |
Subjects were asked every morning to rate on the 11-point S-NRS how leg pain interfered with their sleep quality where 0=did not interfere with sleep and 10=pain completely interfered with sleep.
|
||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
Baseline to Week 52
|
||||||||||||||||
Notes [12] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: Not all arms in the Baseline Period are applicable for this endpoint. |
|||||||||||||||||
|
|||||||||||||||||
Notes [13] - Study was terminated; only Key Secondary endpoints were analysed. [14] - Study was terminated; only Key Secondary endpoints were analysed. [15] - Study was terminated; only Key Secondary endpoints were analysed. |
|||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||
End point title |
Change from Baseline to Week 52 in the Brief Pain Inventory (BPI)-Interference Index [16] | ||||||||||||||||
End point description |
BPI Interference Index is an 11-point numeric rating scale (0 - no interference to 10 - interferes completely) to assess pain-related interference in 7 areas: general activity, mood, walking ability, normal work, including outside the home and housework, relations with other people, enjoyment of life and sleep.
|
||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
Baseline to Week 52
|
||||||||||||||||
Notes [16] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: Not all arms in the Baseline Period are applicable for this endpoint. |
|||||||||||||||||
|
|||||||||||||||||
Notes [17] - Study was terminated; only Key Secondary endpoints were analysed. [18] - Study was terminated; only Key Secondary endpoints were analysed. [19] - Study was terminated; only Key Secondary endpoints were analysed. |
|||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||
End point title |
Change from Baseline to Week 52 in the BPI - Pain Index [20] | ||||||||||||||||
End point description |
BPI- Pain Index for pain intensity, is used to assess potential pain quality descriptors that may describe subjects' pain on a scale of 0 (no pain) to 10 (pain as bad as you can imagine).
|
||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
Baseline to Week 52
|
||||||||||||||||
Notes [20] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: Not all arms in the Baseline Period are applicable for this endpoint. |
|||||||||||||||||
|
|||||||||||||||||
Notes [21] - Study was terminated; only Key Secondary endpoints were analysed. [22] - Study was terminated; only Key Secondary endpoints were analysed. [23] - Study was terminated; only Key Secondary endpoints were analysed. |
|||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||
End point title |
Change from Baseline to Week 52 on the EuroQoL 5-Dimension 5-Level Questionnaire (EQ-5D-5L) Health Index [24] | ||||||||||||||||
End point description |
The EQ-5D-5L is a standardized instrument for use as a measure of health outcome. It is a health questionnaire that consists of the EQ-5D descriptive system and the EQ visual analogue scale (EQ VAS). The EQ-5D-5L descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels (possible responses): no problems, slight problems, moderate problems, severe problems and extreme problems.
|
||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
Baseline to Week 52
|
||||||||||||||||
Notes [24] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: Not all arms in the Baseline Period are applicable for this endpoint. |
|||||||||||||||||
|
|||||||||||||||||
Notes [25] - Study was terminated; only Key Secondary endpoints were analysed. [26] - Study was terminated; only Key Secondary endpoints were analysed. [27] - Study was terminated; only Key Secondary endpoints were analysed. |
|||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||
End point title |
Change from Baseline to Week 52 in Short Form 36 Questionnaire (SF-36) [28] | ||||||||||||||||
End point description |
SF-36 is a self-administered, generic health status questionnaire consisting of 36 questions that measure 8 health concepts: physical functioning, role limitations due to physical problems, bodily pain, general health perception, vitality, social functioning, role limitations due to emotional problems and mental health. Each of the 8 health concepts has a total possible score of 0-100.
|
||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
Baseline to Week 52
|
||||||||||||||||
Notes [28] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: Not all arms in the Baseline Period are applicable for this endpoint. |
|||||||||||||||||
|
|||||||||||||||||
Notes [29] - Study was terminated; only Key Secondary endpoints were analysed [30] - Study was terminated; only Key Secondary endpoints were analysed [31] - Study was terminated; only Key Secondary endpoints were analysed |
|||||||||||||||||
No statistical analyses for this end point |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse events information
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Timeframe for reporting adverse events |
Up to 398 Days in Study 204
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse event reporting additional description |
Safety Population included all subjects who received at least 1 dose of study treatment in this open-label extension study.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Assessment type |
Systematic | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary used for adverse event reporting
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary name |
MedDRA | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary version |
21.1
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting groups
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
BIIB074 (203:Not Dosed Cohort)
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
BIIB074 (vixotrigine) 350 mg orally twice daily (BID), which could be reduced to 200 mg based on tolerability for up to 12 months in Study 204. (Cohort includes subjects who were not dosed in Study 203.) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
BIIB074 (203:Placebo Cohort)
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
BIIB074 (vixotrigine) 350 mg orally BID, which could be reduced to 200 mg based on tolerability for up to 12 months in Study 204. (Cohort includes subjects who received Placebo for up to 12 weeks in Study 203.) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
BIIB074 (203:BIIB074 200 mg Cohort)
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
BIIB074 (vixotrigine) 350 mg orally BID, which could be reduced to 200 mg based on tolerability for up to 12 months in Study 204. (Cohort includes subjects who received BIIB074 200 mg for up to 12 weeks in Study 203.) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
BIIB074 (203:BIIB074 350 mg Cohort)
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
BIIB074 (vixotrigine) 350 mg orally BID, which could be reduced to 200 mg based on tolerability for up to 12 months in Study 204. (Cohort incudes subjects who received BIIB074 350 mg for up to 12 weeks in Study 203.) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 5% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||||||
Substantial protocol amendments (globally) |
|||||||
Were there any global substantial amendments to the protocol? Yes | |||||||
Date |
Amendment |
||||||
05 Apr 2016 |
Amendment 1 Version 2: • Clarification was added to clinic procedures and laboratory tests for safety assessments, eligibility criteria, prohibited medications, adverse event reporting, and treatment compliance, and to the timing of interim sample size re-estimation.
• Information on serotonin syndrome was added, as requested by the FDA. |
||||||
14 Jul 2016 |
Amendment 2 Version 3: •The maximum dose of paracetamol/acetaminophen in prolonged therapy was reduced to 2.5 g/day, and a restriction to the duration of prolonged therapy was added along with a related discontinuation criterion.
•The number of contraceptives to be used for highly effective contraception was reduced from 2 to 1 (thereafter stated as “effective contraception”).
•Additional follow-up phone call was added to assess safety (SAEs) and C-SSRS.
•Updates to liver chemistry stopping criteria were made.
•Information on the symptoms of serotenergic syndrome was included.
•Guidance text related to inclusion criteria associated with QTc and C-SSRS was added.
•Ethinyl estradiol as a prohibited medication was added.
•Clarification around eligibility of male subjects whose partners are pregnant and the need for males to withdraw if their partner becomes pregnant during the study was added.
•Changes to the withdrawal criteria and inclusion and exclusion criteria were made to consolidate the protocol across different countries. |
||||||
05 May 2017 |
Amendment 3 Version 4: This amendment superseded Version 3 and was implemented to update the nonclinical experience. Specifically, further detail around metabolites and the in vivo safety pharmacology study findings were added to reflect updated data from toxicology studies as well as updated exposure and exposure margin calculations, which are based on current industry-accepted practices.
Other major changes involved:
•Adding assessments for unscheduled visits.
•Updated text related to the dose regimen rationale to describe the probability of human exposure exceeding the exposure at which seizure was observed in 1 dog following administration of a 35 mg/kg BID dose.
•Clarified text related disallowed concomitant therapy. |
||||||
24 May 2017 |
Amendment 4 Version 5: This amendment superseded Version 4 and was implemented primarily to clarify that pregnancy of a female partner should not impact the study status of a male subject during his participation in the study. |
||||||
17 Oct 2017 |
Amendment 5 Version 6: This amendment was not implemented. The primary reason for the amendment was to extend the duration of the study to 24 months from 12 months in order to collect more longitudinal data. |
||||||
07 Jun 2018 |
Amendment 6 Version 7: This amendment superseded Version 5 and was implemented primarily to permit the concomitant use of inhibitors or inducers of cytochrome 3A4 (CYP3A4).
Other major changes involved:
•Adjustments to the order of safety assessments.
•Updates to the nonclinical information related to toxicology.
•Updates to the clinical information related to exposure, PK and safety data, including new SAEs.
•Addition of a benefit/risk statement.
•Removal of vital signs, ECG parameters, laboratory safety tests, and C-SSRS from the primary endpoint.
•Changes to procedure or follow-up when a subject discontinues study treatment due to a rash.
•Addition of text to describe how abuse potential will be assessed during the study. |
||||||
Interruptions (globally) |
|||||||
Were there any global interruptions to the trial? Yes | |||||||
|
|||||||
Limitations and caveats |
|||||||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||||||
None reported |